Publication Topic

Thompson CM, Heintz MM, Rogers SI, Vincent MJ, Haws LC. 2026. Integration of mechanistic and repeat dose toxicity data in the derivation of an oral reference dose for HFPO-DA. Toxicol Sci April 10:kfag045; doi: 10.1093/toxsci/kfag045. Online ahead of print April 10^th. PMID: 41968070.

Killius A, Covell LT. Characterization of PFAS in Vermont public water systems. Abstract 3892, Society of Toxicology 65^th Annual Meeting, San Diego, CA, March 2026.

Killius A, Wheeler M, Covell L, Price S, Finley B. 2026. Derivation of provisional chronic oral toxicity values (PCOTV) for novel short-chain PFAS congeners. J Appl Toxicol; doi: 10.1002/jat.70156. Online ahead of print March 12. PMID: 41814952.

Patlewicz G, Judson, Paul Friedman K, Wetmore BA, DeVito MJ, Harrill JA, Carstens KE, Houck KA, et al. 2026. Insights derived from testing a library of per- and polyfluoroalkyl substances (PFAS) in a battery of new approach methods (NAMs). J Toxicol Environ Health B 29(1):1-69; doi: 10.1080/10937404.2025.2521615. PMID: 40619890.

Thompson CM, Heintz MM, Cullen JM, Haws LC. 2026. Evaluation of chronic toxicity and carcinogenicity of HFPO-DA in mice. Regul Toxicol Pharmacol 165(Feb):106014; doi: 10.1016/j.yrtph.2025.106014. PMID: 41391658.

Garcia MM, Pearce JL, Jacobellis MA, Baldwin WS, Hunt KJ, Bain LJ. 2025. Mixtures of p,p′-DDE, PCB153, BDE47, and PFOS alter adipocytic differentiation of 3T3-L1 cells. Toxics 13(11):975; doi: 10.3390/toxics13110975. PMID: 41304527.

Baldwin WS, Bloom MS, Chung KW, Dasgupta S, DeLorenzo ME, Hunt KJ, Key PB,…, Jacobellis MA, et al. 2025. Toxicological, chemical, social, and economic challenges associated with PFAS and replacement aqueous film-forming foams (AFFF). Toxics 13(9):732; doi: 10.3390/toxics13090732. PMID: 41012353.

Kenyon EM, DeVito MJ, Patlewicz G, Adams LD, Thomas RS, Ambroso JL, Yang X, Blake JC, et al. 2025. Subchronic toxicity of four per- and polyfluoroalkyl substances by oral exposure in Sprague Dawley rats. Toxics 13(7):524; doi: 10.3390/toxics13070524. PMID: 40710969.

Hughes MF, DeVito MJ, Patlewicz G, Thomas RS, Adams LD, Ambroso JL, Yang X, Upadhyay BG, et al. 2025. Immunotoxicity of four per- and polyfluoroalkyl substances following 28-day oral repeat dosing in rats assessed by the anti-sheep red blood IgM response. Toxics 13(6):490; doi: 10.3390/toxics13060490. PMID: 40559963.

Heintz MM, Buerger AN, Haws LC, East AW, Cullen JM, Thompson CM. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mice. Abstract 3972, Society of Toxicology 64^th Annual Meeting, Orlando, FL, March 2025

Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. 2025. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: A case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci 204(1):96-115; doi: 10.1093/toxsci/kfae152. PMID: 39792025.

Patlewicz G, Judson RS, Williams AJ, Butler T, Barone Jr. S, Carstens K, Cowden J, Dawson JD, et al. 2024. Development of chemical categories for per- and polyfluoroalkyl substances (PFAS) and the proof-of-concept approach to the identification of potential candidates for tiered toxicological testing and human health assessment. Comput Toxicol 131(Sep 1):100327; doi: 10.1016/j.comtox.2024.100327. PMID: 40547594.

Lin HC, Sakolish C, Moyer HL, Carmichael PL, Baltazar MT, Ferguson SS, Stanko JP, Hewitt P, et al. 2024. An in vitro-in silico workflow for predicting renal clearance of PFAS. Toxicol Appl Pharmacol 489(Aug):117015; doi: 10.1016/j.taap.2024.117015. PMID: 38917890.

Judson RS, Smith D, DeVito M, Wambaugh JF, Wetmore BA, Paul Friedman K, Patlewicz G, Thomas RS, et al. 2024. A comparison of in vitro points of departure with human blood levels for per- and polyfluoroalkyl substances (PFAS). Toxics 12(4):271; doi: 10.3390/toxics12040271. PMID: 38668494.

Kougias DG, Killius A, Collins J, Russman E, Maddaloni M. 2024. Per- and polyfluoroalkyl substances (PFAS) in drinking water: A retrospective case series with risk assessments. Chapter 7 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 337–396.

Covell LT, Donnell MT, Keeton KA, Madl AK. Human health risk assessment of per- and polyfluoroalkyl substances (PFAS) in facial cosmetics. Poster presentation P342/Late-Breaking Abstract 5240, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Lin H, Sakolish C, Moyer HL, Ferguson SS, Stanko JP, Carmichael PL, Hewitt P, Hoffmann S, et al. Predicting renal clearance of PFAS with a human kidney proximal tubule tissue chip and a novel physiologically-based kidney model. Abstract 3508, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Thompson CM, Heintz MM, Rogers SI, Fitch SE, Rivera BN, Klaren WD, Vincent MJ, Wikoff DS, Haws LC. Evidence identification and appraisal supporting development of an updated toxicity value for HFPO-DA. Abstract 3654, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

Shirke AV, Radke EG, Lin C, Blain R, Vetter N, Lemeris C, Hartman P,.., Patlewicz G, et al. 2024. Expanded systematic evidence map for hundreds of per- and polyfluoroalkyl substances (PFAS) and comprehensive PFAS human health dashboard. Environ Health Perspect 132(2):026001; doi: 10.1289/EHP134. PMID: 38319881.